Kiran Mazumdar-Shaw: From a Bengaluru Garage to Global Biopharma
She started Biocon in 1978 with little more than a garage and a stubborn idea. Nearly five decades later, she is shaping its next chapter, and choosing who will lead it.

Executive Key Takeaways
- Kiran Mazumdar-Shaw founded Biocon in a Bengaluru garage in 1978.
- Biosimilars earned Rs 10,431 crore in FY26 and make up over 60% of revenue.
- Biocon is expanding into GLP-1 drugs for diabetes and weight management.
- She has named her niece, Claire Mazumdar, as her eventual successor.
Kiran Mazumdar-Shaw's founding story is one of the best known in Indian business, and it still surprises people. Trained as a master brewer in Australia, she returned home to Bengaluru in the 1970s expecting to work in the brewing industry. No one would hire a woman for the job.
So she built her own company instead. In 1978, she started Biocon in a rented garage with a few thousand rupees in capital, making industrial enzymes. Banks were reluctant to lend to a young woman in a field few Indians had heard of, and many early recruits doubted the venture would last.
It did. Biocon grew from enzymes into insulin, then into biologic medicines, becoming one of India's most important biopharmaceutical companies. Its 2004 stock market listing was a landmark for the country's biotech sector.
The biosimilars bet
Today, the heart of Biocon is biosimilars: lower-cost, highly similar versions of complex biologic drugs whose patents have expired. In the 2026 financial year, the biosimilars business brought in Rs 10,431 crore in revenue, up 16%, with adjusted earnings before interest, tax, depreciation and amortisation up 40% to Rs 2,751 crore. Biosimilars now account for more than 60% of Biocon's consolidated revenue.
The opportunity ahead is large. Mazumdar-Shaw points to a wave of patent expiries on biologic medicines over the coming decade. Biocon has a 20-product biosimilars pipeline and recently launched two denosumab biosimilars in the United States, Bosaya and Aukelso, referencing the bone-health drugs Prolia and Xgeva.
After years of heavy spending on manufacturing plants, Biocon says it has finished its major investment cycle. The focus now is on using those plants fully, improving margins and lifting returns.
Entering the obesity era
Biocon is also moving into one of medicine's fastest-growing markets: GLP-1 drugs for diabetes and weight management. It has launched liraglutide in Europe and the United States, where it secured FDA approval for a generic version covering both diabetes and weight loss. It is preparing semaglutide launches in emerging markets.
Mazumdar-Shaw argues that Biocon's long history in insulin gives it a unique position. In her view, it will be the only company with both an insulin portfolio and GLP-1 medicines, two pillars of modern diabetes care.
A company rebuilt for the next phase
Biocon's overall numbers reflect a business in transition. Consolidated total income rose 14% to Rs 17,270 crore in the 2026 financial year, with operating profit margins of about 22%. The company is merging its biosimilars, generic formulations and active pharmaceutical ingredients businesses into a single global biopharma platform.
Leadership is changing too. Shreehas Tambe became chief executive and managing director on April 1, 2026, as Biocon moved from what it called a “Preserve” phase to a “Consolidate” phase.
Planning the succession
In May 2026, Mazumdar-Shaw named her niece, Claire Mazumdar, as her eventual successor. Claire trained in biological engineering at MIT and in cancer biology at Stanford, and built Bicara Therapeutics into a Nasdaq-listed company valued at more than $1 billion.
The announcement prompted speculation that the founder was stepping back. She quickly corrected it, writing that Claire would take over “at the right time” and that she was not planning to hang up her boots just yet.
Few founders speak so openly about succession while still firmly in charge. It is a mark of how she sees Biocon: as an institution meant to outlast her.
Beyond the company
Mazumdar-Shaw has long used her platform beyond business. She is a signatory of the Giving Pledge and has funded healthcare initiatives in India, including cancer care in Bengaluru. She is also an outspoken voice on science policy and India's place in global life sciences.
What leaders can learn
Her career offers a lesson in turning exclusion into opportunity. Denied entry to one industry, she built a new one. Decades later, she is showing a second, rarer skill: planning openly for the day someone else runs what she built.
“Claire will transition into my role at the right time so not planning to hang up my boots just yet!!”
Frequently Asked Questions
Key Questions Answered
Related Research & Coverage
Explore Further
More in Industry Spotlight
Jane Fraser: The Banker Who Rebuilt Citi
When she took charge in 2021, plenty of people doubted anyone could fix Citigroup. Five years later, she is ranked the most powerful woman in business, and Citi is talking about growth again.
Mary Barra: Twelve Years at the Wheel of GM
The longest-serving chief executive among Detroit's Big Three is steering through tariffs, policy reversals and an uncertain electric-vehicle market, and still gaining ground.
